Notified bodies under the IVD (In Vitro Diagnostics) Directive will be private-public collaborations
This article was originally published in Clinica
Third party testing and certification organisations throughout the EU are vying to link up with public sector laboratories to ensure they will have access to the large number of human specimens necessary for testing purposes to qualify for notified body status under the In Vitro Diagnostics Directive (IVDD).
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.